FDA Safety Warnings or Clinical Trial Findings on Tirzepatide As of 2024, the FDA has not issued a black box warning specific to Zepbound, but it shares the same class-wide warning found on other GLP-1 drugs like Wegovy and Ozempic: a potential link to thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)
EU Revoked Patents on Oral Semaglutide EP2827845, covering a delivery agent composition for the tablet form (Rybelsus) EP2827885, related to GLP-1 peptide compositions
When Wegovy launched in June 2021, Novo Nordisk struggled to meet demand, announcing a shortage in December 2021 due to manufacturing issues
If the insurance company isnt being fair, we know exactly how to get them to take your case seriously
To figure out the best weight management medication for you, its important to talk with your prescriber
If results from a research chemical product fall significantly below what clinical trials show for pharmaceutical semaglutide at equivalent doses, product quality is the most likely explanation
